Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KANDOVA
2022-002792-11Phase 2Active
- Sponsor
- Kancera
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rugocrixan in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Kancera. Primary endpoint: Safety and tolerability. Started Jan 2023; status: active.
02
Drugs
rugocrixan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2022-002792-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002792-11.